bivamelagon vs setmelanotide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypothalamic Obesity
Shared mechanism: MC4R · full Hypothalamic Obesity pipeline
bivamelagon
Developed by Rhythm Pharmaceuticals under a licence from LG Chem
NCT06046443 · Phase 2 · completed
This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2028 · NCT07156578 (registry estimate)
Reported efficacy
Mean percentage change in BMI (From Baseline to Week 14): Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2% (met)
Result source: NCT06046443
setmelanotide · Imcivree
Marketed by Rhythm Pharmaceuticals
NCT05774756 · Phase 3 · active, not recruiting
This was a randomized, triple-blind, placebo-controlled trial whose primary endpoint, percent change in BMI, was clearly met (difference of about 20 percentage points, p<0.0001). The trial enrolled the 120 pivotal participants its reported power calculation required.
Next expected readout: March 2027 · NCT06760546 (registry estimate)
Reported efficacy
Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) (met)
Result source: NCT05774756
Results for Hypothalamic Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. bivamelagon: 0 of 4 rows · setmelanotide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bivamelagon | setmelanotide |
|---|---|---|
| Dropout rate | — | 11.1%a NCT04725240 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 11.1%a NCT04725240 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 5.6%a NCT04725240 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | a nausea 61.1% skin hyperpigmentation 33.3% vomiting 33.3% NCT04725240 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bivamelagon
show 2 more results
setmelanotide
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bivamelagon's landscape · setmelanotide's landscape